We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ligand Pharmaceuticals (LGND) Suffers a Larger Drop Than the General Market: Key Insights
Read MoreHide Full Article
The latest trading session saw Ligand Pharmaceuticals (LGND - Free Report) ending at $72.19, denoting a -1.84% adjustment from its last day's close. This change lagged the S&P 500's daily loss of 0.07%.
Shares of the drugmaker have appreciated by 9.3% over the course of the past month, outperforming the Medical sector's gain of 7.37% and the S&P 500's gain of 3.98%.
The investment community will be closely monitoring the performance of Ligand Pharmaceuticals in its forthcoming earnings report. The company is forecasted to report an EPS of $0.58, showcasing a 57.35% downward movement from the corresponding quarter of the prior year. Simultaneously, our latest consensus estimate expects the revenue to be $24.54 million, showing a 51.29% drop compared to the year-ago quarter.
Any recent changes to analyst estimates for Ligand Pharmaceuticals should also be noted by investors. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. The Zacks Consensus EPS estimate has moved 3.16% lower within the past month. Right now, Ligand Pharmaceuticals possesses a Zacks Rank of #4 (Sell).
Looking at its valuation, Ligand Pharmaceuticals is holding a Forward P/E ratio of 16.64. For comparison, its industry has an average Forward P/E of 22.75, which means Ligand Pharmaceuticals is trading at a discount to the group.
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 61, positioning it in the top 25% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Ligand Pharmaceuticals (LGND) Suffers a Larger Drop Than the General Market: Key Insights
The latest trading session saw Ligand Pharmaceuticals (LGND - Free Report) ending at $72.19, denoting a -1.84% adjustment from its last day's close. This change lagged the S&P 500's daily loss of 0.07%.
Shares of the drugmaker have appreciated by 9.3% over the course of the past month, outperforming the Medical sector's gain of 7.37% and the S&P 500's gain of 3.98%.
The investment community will be closely monitoring the performance of Ligand Pharmaceuticals in its forthcoming earnings report. The company is forecasted to report an EPS of $0.58, showcasing a 57.35% downward movement from the corresponding quarter of the prior year. Simultaneously, our latest consensus estimate expects the revenue to be $24.54 million, showing a 51.29% drop compared to the year-ago quarter.
Any recent changes to analyst estimates for Ligand Pharmaceuticals should also be noted by investors. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. The Zacks Consensus EPS estimate has moved 3.16% lower within the past month. Right now, Ligand Pharmaceuticals possesses a Zacks Rank of #4 (Sell).
Looking at its valuation, Ligand Pharmaceuticals is holding a Forward P/E ratio of 16.64. For comparison, its industry has an average Forward P/E of 22.75, which means Ligand Pharmaceuticals is trading at a discount to the group.
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 61, positioning it in the top 25% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.